Kuru göz sendromu

Kuru göz sendromu (KGS), oküler yüzeye hasar verme potansiyeline sahip yangı, gözyaşı film osmolaritesinin artışı, instabilitesi ve görme bozukluğu ile karakterize multifaktöriyel bir hastalıktır. Hastalığın insanlarda kadın ve yaşlılarda, hayvanlarda ise köpeklerde yaygın olduğu bildirilmiştir. Bu derlemede KGS’nin özellikle insidensi, nedenleri, patogenezisi, teşhis ve tedavisi güncel literatürler ışığında değerlendirilmiştir. Mevcut derlemenin KGS konusunda kolay uygulanabilen, ekonomik ve etkili tedavi alternatiflerinin geliştirilebilmesini planlayan genç araştırıcılar ve klinisyenler için yararlı olacağı kanısına varılmıştır.

Dry eye syndrome

Dry eye syndrome (DES) is a multifactorial disease characterized by inflammation, increased tear osmalarity and instability as well as vision impairment. It is common in women and elderly among humans and a prevalent disease in dogs within the animals. In this review, DES has been evaluated in light of the recent literatures paying particular attentions to its incidence, causes, pathogenesis, diagnosis and treatment. It was suggested that the current review may be useful for the young researchers and clinicians who plan to develop easy-to-apply, economical and effective treatment modalities for DES.

PDF

___

1. Report of the Definition, Classification, Management and Therapy Subcommittee of the International Dry Eye WorkShop 2007; Ocul Surf. 5(2): 1-163.
2. Alkan F, İzci C, Tepeli C, Koç Y. Evaluation of the schirmer tear test in clinically normal Turkish hunting dogs (Turkish Greyhound). Vlaams Diergeneeskundig Tijdschrift 2004; 73: 269-273.
3. Barnett KC, Sansom J. Dry eye in the dog and it’s treatment. Trans Ophthalmogy 1985; 104(4): 462-466.
4. Gelatt KN. Essentials of veterinary ophthalmology. London: Lippincott Wilkins, 2000.
5. Almeida DED, Mamede FV, Ortiz JP, Laus JL. Iatrogenic keratoconjunctivitis sicca in a dog. Ciencia Rural 2004; 34 (3): 921-924.
6. Foulks GN. Pharmacological management of dry eye in the elderly patient. Drugs Aging 2008; 25(2):105-118.
7. Gelatt KN. Veterinary Ophthalmology. 2nd Edition, London: Lea£ Febijer, 1991.
8. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003; 136(2): 318-326.
9. Wolkoff P, Kjaergaard SK. The dichotomy of relative humidity on indoor air quality. Environ Int 2007; 33(6): 850- 857.
10. Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 2008; 14(3 Suppl): S79- 587.
11. Kjaergaard SK, Hempel-Jørgensen A, Mølhave L, et al. Eye trigeminal sensitivity, tear film stability and conjunctival epithelium damage in 182 non-allergic, non-smoking Danes. Indoor Air 2004; 14(3): 200-207.
12. Khurana AK, Choudhary R, Ahluwalia BK, Gupta S. Hospital epidemiology of dry eye. Indian J Ophthalmol 1991; 39(2): 55-58.
13. Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br J Ophthalmol 2007; 91(1): 47-50.
14. Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmaol 2008; 126(2): 219-225.
15. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002; 966: 211-222.
16. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106(3): 556-563.
17. Yoon KC, Im SK, Seo MS. Changes of tear film and ocular surface in diabetes mellitus. Korean J Ophthalmol 2004; 18(2):168-174.
18. Giuliano EA. Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology. Vet Clin Am Small Anim Prac 2004; 34(3): 707-723.
19. Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea 2007; 26(1): 84-89.
20. Gayton JL. Etiology, prevalance, and treatment of dry eye disease. Clinical Ophthalmology 2009; 3: 405-412.
21. McCabe E, Narayanan S. Advancements in antiinflammatory therapy for dry eye syndrome. Optometry 2009; 80(10): 555-566.
22. Rolando M, Zierhut M. The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol 2001; 45 Suppl 2: 203-210.
23. De Paiva CS, Pflugfelder SC. Rationale for antiinflammatory therapy in dry eye syndrome. Arq Bras Oftalmol 2008; 71(6 Suppl): 89-95.
24. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 2009; 50(7): 3203-3209.
25. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 2005; 166(1): 61-71.
26. Gumus K, Cavanagh DH. The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol 2009; 3: 57-67.
27. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stres Invest Ophthalmol Vis Sci 2007; 48(6): 2561-2569.
28. Foster CS, Yuksel E, Anzaar F, Ekong AS. Dry Eye Syndrome. eMedicine Specialties, Ophthalmology, Lacrimal System. Updated: Nov 15, 2010.
29. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004; 23(8): 762-770.
30. Anonim. “Optometric clinical practice guideline: care of the patient with ocular surface disorders”. http://www.aoa.org/documents/CPG-10.pdf. 2002, updates April and June 2003/ 13.03.2008.
31. Anonim. “Keratoconjunctivitis sicca (Dry Eye)”. Page 1-2, http:www.memorial-610hospital.net/10.10.2009.
32. Davidson HJ, Kuonen VJ. Tear film and ocular mucins. Vet Ophthalmol 2004; 7(2): 71-77.
33. Berdoulay A, English RV, Nadelstein B. Effect of topical % 0.02 tacrolimus aqueous suspension on tear production in dogs with keratokonjunktivitis sicca. Vet Ophthalmol 2005; 8(4): 225- 226.
34. McLellan GL, Archer FJ. Corneal stromal sequestration and keratoconjunctivitis sicca in a horse. Vet Ophthalmol 2000; 3(2-3): 207-212.
35. Nell B, Walde I, Billich A, Vit P, Meingassner JG. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 2005; 8(1): 39-46.
36. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol 2001; 45 Suppl 2: 221-226.
37. Savini G, Prabhawasat P, Kojima T, et al. The challenge of dry eye diagnosis. Clin Ophthalmol 2008; 2(1): 31-55.
38. Barabino S, Chen W, Dana MR. Tear film and ocular surface tests in animal models of dry eye: uses and limitations. Exp Eye Res. 2004; 79(5):613-621.
39. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clinical and experimental Optometry, 2001; 84 (1): 4-18.
40. Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. Ophthalmology 1992; 99(4): 605-617.
41. Feenstra RP, Tseng SC. What is actually stained by rose bengal? Arch Ophthalmol 1992; 110(7): 984-993.
42. Machado LM, Castro RS, Fontes BM. Staining patterns in dry eye syndrome: rose bengal versus lissamine gren. Cornea 2009; 28(7): 732-734.
43. Kim J, Foulks GN. Evaluation of the effect of lissamine green and rose bengal on human corneal epithelial cells. Cornea 1999; 18(3): 328-332.
44. Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci 2009; 50(8): 3671-3689.
45. Gilbard JP, Rossi SR, Heyda KG. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology 1989; 96(8): 1180- 1186.
46. Gilbard JP, Rossi SR, Gray KL, Hanninen LA, Kenyon KR. Tear film osmolarity and ocular surface disease in two rabbit models for keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 1988; 29(3): 374-378.
47. De Paiva CS, Pflugfelder SC. Tear clearance implications for ocular surface health. Experimental Eye Research 2004; 78: 395-397.
48. Afonso AA, Monroy D, Stern ME, et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999; 106(4): 803-810.
49. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2002; 43(3): 632-638.
50. Erdogan-Poyraz C, Mocan MC, Irkec M, Orhan M. Delayed tear clearance in patients with conjunctivochalasis is associated with punctal occlusion. Cornea 2007; 26(3): 290-293.
51. Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol 1998; 82(6): 666-675.
52. Xu KP, Tsubota K. Correlation of tear clearance rate and fluorophotometric assessment of tear turnover. Br J Ophthalmol 1995; 79(11): 1042-1045.
53. Xu KP, Yagi Y, Toda I, Tsubota K. Tear function index. A new measure of dry eye. Arch Ophthalmol 1995; 113(1): 84-88.
54. Macri A, Rolando M, Pflugfelder S. A Standardized visual scale for evaluation of tear fluorescein clearance. American Academy of Ophthalmology 2000; 107: 1338-1343.
55. Hamano HM, Hori M, Hamano T, et al. A new method for measuring tears. CLAO J 1983; 9: 281-289.
56. Asbell PA, Chiang B. Phenol-red thread test compared to Schirmer test in normal subjects. Ophthalmol 1987; 94(Suppl): 128.
57. Barabino S, Shen L, Chen L, et al. The controlledenvironment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005; 46(8): 2766-2771.
58. Inatomi T, Spurr-Michaud S, Tisdale AS, et al. Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophthalmol Vis Sci 1996; 37(8): 1684-1692.
59. Altinors DD, Bozbeyoglu S, Karabay G, Akova YA. Evaluation of ocular surface changes in a rabbit dry eye model using a modified impression cytology technique. Curr Eye Res 2007; 32(4): 301-307.
60. Gipson IK, Tisdale AS. Visualization of conjunctival goblet cell actin cytoskeleton and mucin content in tissue whole mounts. Exp Eye Res 1997; 65(3): 407-415.
61. Huang AJ, Tseng SC, Kenyon KR. Morphogenesis of rat conjunctival goblet cells. Invest Ophthalmol Vis Sci 1988; 29(6): 969-975.
62. Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol. 1983; 101(12): 1869-1872.
63. Ohashi Y, Dogru M, Tsubota K. Laboratory findings in tear fluid analysis. Clinica Chimica Acta 2006; 369: 17-28.
64. Yüksel B, Bozdag B, Acar M, Topaloglu E. Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur J Ophthalmol 2010; 20(4): 675-679.
65. Bolzan AA, Brunelli AT, Castro MB, et al. Conjunctival impression cytology in dogs. Vet Ophthalmol 2005; 8(6): 401-405.
66. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999; 106(4): 811-6.
67. Aragona P, Stilo A, Ferreri F, Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients. Eye (Lond), 2005; 19(5):535-539.
68. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology, 2000; 47(2-3): 119- 125.
69. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997; 133(1): 49-54.
70. Mathers WD, Stovall D, Lane JA, Zimmerman MB, Johnson S. Menopause and tear function: The influence of prolactin and sex hormones on human tear production. Cornea 1998; 17(4): 353-358.
71. Selek H, Unlu N, Orhan M, Irkeç M. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol 2000; 10(2): 121-127.
72. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: Clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85(10): 1188-1197.
73. Mah FS, O’Brien T, Kim T, Torkilsen G. Evaluation of the effects of olopatadine ophthalmic solution, % 0.2 on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin 2008; 24(2): 441-447.
74. Lekhanont K, Park CY, Combs JC, et al. Effect of topical olopatadine and epinastine in the botulinum toxin Binduced Mouse model of dry eye. J Ocul Pharmacol Ther 2007; 23(1): 83-88.
75. Schalnus R. Topical Nonsteroidal Anti-Inflammatory Therapy in Ophthalmologica. 2003; 217: 89-98.
76. Lekhanont K, Park CY, Smith JA, et al. Effects of Topical Anti-inflammatory Agents in a Botulinum Toxin B-İnduced Mouse Model of Keratoconjunctivitis Sicca. J Ocul Pharmacol Ther 2007; 23(1): 27-34.
77. Calonge M. The Treatment of Dry Eye. Survey ophthalmology, 2001; 45(2): 227-239.
78. Lemp MA. Management of dry eye disease. Am J Manag Care 2008; 14(3 Suppl): S88-101.
79. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86(2): 181-184.
80. Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea 2007; 26(1): 84-89.
81. Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B 2006; 7(8): 675-678.
82. Nagelhout TJ, Gamache DA, Roberts L, Brady MT, Yanni JM. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J Ocul Pharmacol Ther 2005; 21(2): 139-148.
83. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004; 138(3): 444-457.
84. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136(4): 593-602.
85. Lee SY, Ubels JL, Soprano DR. The lacrimal gland synthesizes retinol-binding protein. Exp Eye Res 1992; 55(1): 163-171.
86. Kobayashi TK, Tsubota K, Takamura E, et al. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica 1997; 211(6): 358-361.
87. Tseng SC. Topical retinoid treatment for dry eye disorders. Trans Ophthalmol Soc U K 1985; 104 (Pt 4): 489-495.
88. Soong HK, Martin NF, Wagoner MD, et al. Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled doublemasked study. Ophthalmol 1988; 95(10): 1442-1446.
89. Fukushima A, Yamaguchi T, Ishida W, et al. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Experiment Ophthalmol 2006; 34(4): 347-353.
90. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders Br J Ophthalmol 2005; 89(10): 1363-1367.
91. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008; 126(8):1046-1050.
92. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118(11): 1489-1496.
93. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120(3): 330-337.
94. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000; 19(4):492-496.
95. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999; 878: 271-289.
96. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 1994; 732: 140-151.
97. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent 1998; 12(2):114-118.
98. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45(12): 4302-4311.
99. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci 2006; 47(7): 2847-2856.
100. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000; 41(9): 2544-2557.
101. Corum I, Yeniad B, Bilgin LK, Ilhan R. Efficency of olopatadine hydrochloride % 0.1 in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 2005; 21(5): 400-405.
102. Villareal AL, Farley W, Pflugfelder SC. Effect of topical epinastine and olopatadine on tear volume in mice. Eye Contact Lens 2006; 32(6): 272-276.
103. Akın F, Samsar E. Göz Hastalıkları, Ankara: Medipres Matbaacılık, 2001.